Crossmark

Advances in new therapeutic targets for atherosclerosis

Crossref DOI link: https://doi.org/10.1038/nrcardio.2016.216

Published Online: 2017-01-17

Published Print: 2017-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tang, W. H. Wilson

Hazen, Stanley L.
License Information

Text and Data Mining valid from 2017-01-17
More Information

Article History

First Online: 17 January 2017

Competing interests

: S.L.H. is named as inventor on pending patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics. He is also a paid consultant for Esperion and P&G, and has received research funds from Astra Zeneca, P&G, Pfizer Inc., Roche Diagnostics, and Takeda. S.L.H. has also received royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland HeartLab, Esperion, Frantz Biomarkers, LLC, and Siemens. W.H.W.T. declares no competing interests.